Publications:
Our Research

Real-world evaluation of 2023–2024 XBB.1.5 mRNA and protein-based COVID-19 vaccine reactogenicity from the randomized BEEHIVE trial

Real-World Utilization of the Novavax Adjuvanted Recombinant Protein COVID-19 Vaccine in France During the 2022–2024 Period

The platform trial in COVID-19 priming and BOOsting (PICOBOO): The reactogenicity of nine licensed COVID-19 vaccines delivered in immunocompetent adults

Real-world effectiveness and safety of protein-based and mRNA COVID-19 vaccines (BEEHIVE trial). Vaccine 2026; 88,128954.

Intranasal and intramuscular H5-Matrix-M nanoparticle vaccines protects against highly pathogenic H5N1 influenza virus in mice.

Safety and immunogenicity of a COVID-19–Influenza Combination nanoparticle vaccine (CIC) containing SARS-CoV-2 recombinant spike and quadrivalent influenza hemagglutinin with Matrix-M® adjuvant: A phase 1/2 clinical trial.

Validation of a Mucosal IgA Assay for SARS-CoV-2

Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2 Omicron JN.1 and LP.8.1 Subvariant Lineage Strains with Homologous and Heterologous Matched Sera in Clinically Relevant Samples

The Platform trial In COVID-19 priming and BOOsting (PICOBOO): the reactogenicity of nine licensed COVID-19 vaccines delivered in immunocompetent adults

mRNA and Protein Subunit COVID-19 Vaccine Reactogenicity and Their Relationship to Productivity for Healthcare Workers and First Responders